Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$1.1 - $2.45 $14,960 - $33,320
-13,600 Reduced 9.68%
126,900 $157,000
Q3 2022

Nov 14, 2022

SELL
$1.96 - $3.32 $80,752 - $136,784
-41,200 Reduced 22.67%
140,500 $289,000
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $92,843 - $198,774
40,900 Added 29.05%
181,700 $503,000
Q1 2022

May 16, 2022

BUY
$3.69 - $5.65 $46,125 - $70,625
12,500 Added 9.74%
140,800 $615,000
Q4 2021

Feb 14, 2022

BUY
$5.37 - $7.07 $241,113 - $317,443
44,900 Added 53.84%
128,300 $708,000
Q3 2021

Nov 15, 2021

SELL
$5.54 - $7.51 $39,334 - $53,321
-7,100 Reduced 7.85%
83,400 $515,000
Q2 2021

Aug 11, 2021

SELL
$7.78 - $11.4 $494,030 - $723,900
-63,500 Reduced 41.23%
90,500 $769,000
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $715,776 - $1.19 Million
139,800 Added 984.51%
154,000 $1.22 Million
Q4 2020

Feb 16, 2021

SELL
$3.16 - $7.03 $106,176 - $236,208
-33,600 Reduced 70.29%
14,200 $83,000
Q3 2020

Nov 16, 2020

SELL
$3.26 - $4.73 $200,490 - $290,895
-61,500 Reduced 56.27%
47,800 $162,000
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $127,190 - $372,715
80,500 Added 279.51%
109,300 $504,000
Q4 2019

Feb 14, 2020

SELL
$2.25 - $3.07 $310,050 - $423,046
-137,800 Reduced 82.71%
28,800 $79,000
Q3 2019

Nov 14, 2019

SELL
$2.67 - $3.65 $289,695 - $396,025
-108,500 Reduced 39.44%
166,600 $490,000
Q2 2019

Aug 14, 2019

BUY
$2.6 - $4.21 $125,060 - $202,501
48,100 Added 21.19%
275,100 $790,000
Q1 2019

May 15, 2019

BUY
$3.05 - $4.34 $352,885 - $502,138
115,700 Added 103.95%
227,000 $953,000
Q3 2018

Nov 14, 2018

BUY
$1.45 - $6.15 $161,385 - $684,495
111,300 New
111,300 $484,000
Q2 2018

Aug 14, 2018

SELL
$1.65 - $2.5 $69,795 - $105,750
-42,300 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$1.25 - $2.65 $52,875 - $112,095
42,300 New
42,300 $78,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $472M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.